Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma

被引:10
作者
Fan, Weiqiang [1 ]
Ma, Huan [1 ]
Jin, Bin [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Organ Transplantat, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China
关键词
forkhead box protein M1; polo-like kinase 1; hepatocellular carcinoma; cell cycle; M1 TRANSCRIPTION FACTOR; POLO-LIKE KINASES; POOR-PROGNOSIS; CLINICOPATHOLOGICAL FEATURES; IMMUNE LANDSCAPE; INHIBITOR; CELLS; PHOSPHORYLATION; OVEREXPRESSION; BEVACIZUMAB;
D O I
10.3892/ol.2022.13266
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma (HCC) is one of the most frequently encountered malignant tumor types and to improve its treatment, effective prognostic biomarkers are urgently required. Cell cycle dysregulation is a significant feature of cancer progression. The aim of the present study was to estimate the expression levels of forkhead box protein M1 (FOXM1) and polo-like kinase 1 (PLK1), both of which have essential roles in cell cycle regulation, and determine their prognostic value in HCC. To this end, FOXM1 and PLK1 expression levels were assessed in The Cancer Genome Atlas and International Cancer Genome Consortium Japan HCC cohorts, and the associations between their co-expression were determined via Pearson's correlation analysis. Furthermore, the overall survival and disease-free survival in these cohorts for different FOXM1 and PLK1 expression statuses were analyzed. In vitro knockdown experiments were also performed using Huh7 cells. The results obtained indicated overexpression of FOXM1 and PLK1 in HCC tumor tissues as well as a positive correlation between FOXM1 and PLK1 expression. The results also suggested that both FOXM1 and PLK1 are required for HCC cell proliferation. In addition, upregulation of FOXM1 and PLK1 was indicated to be associated with poor prognosis of patients with HCC. However, only their coordinated overexpression was identified as an independent prognostic factor for HCC.
引用
收藏
页数:12
相关论文
共 56 条
  • [1] Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets
    Agarwal, Rahul
    Narayan, Jitendra
    Bhattacharyya, Amitava
    Saraswat, Mayank
    Tomar, Anil Kumar
    [J]. CANCER GENETICS, 2017, 216 : 37 - 51
  • [2] Polo-like kinases and the orchestration of cell division
    Barr, FA
    Silljé, HHW
    Nigg, EA
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (06) : 429 - 440
  • [3] Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications
    Cariani, Elisabetta
    Missale, Gabriele
    [J]. LIVER INTERNATIONAL, 2019, 39 (09) : 1608 - 1621
  • [4] FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1
    Chai, Na
    Xie, Hua-hong
    Yin, Ji-peng
    Sa, Ke-di
    Guo, Yi
    Wang, Meng
    Liu, Jun
    Zhang, Xiao-fang
    Zhang, Xiang
    Yin, Hong
    Nie, Yong-zhan
    Wu, Kai-chun
    Yang, An-gang
    Zhang, Rui
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 500 (04) : 924 - 929
  • [5] A Conserved Phosphorylation Site within the Forkhead Domain of FoxM1B Is Required for Its Activation by Cyclin-CDK1
    Chen, Yi-Ju
    Dominguez-Brauer, Carmen
    Wang, Zebin
    Asara, John M.
    Costa, Robert H.
    Tyner, Angela L.
    Lau, Lester F.
    Raychaudhuri, Pradip
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (44) : 30695 - 30707
  • [6] Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
    Cheng, Li
    Wang, Chongchong
    Jing, Juehua
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (10) : 1347 - 1350
  • [7] Regulating a key mitotic regulator, polo-like kinase 1 (PLK1)
    Colicino, Erica G.
    Hehnly, Heidi
    [J]. CYTOSKELETON, 2018, 75 (11) : 481 - 494
  • [8] Playing polo during mitosis: PLK1 takes the lead
    Combes, G.
    Alharbi, I.
    Braga, L. G.
    Elowe, S.
    [J]. ONCOGENE, 2017, 36 (34) : 4819 - 4827
  • [9] FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas
    Dibb M.
    Han N.
    Choudhury J.
    Hayes S.
    Valentine H.
    West C.
    Sharrocks A.D.
    Ang Y.S.
    [J]. BMC Research Notes, 8 (1)
  • [10] Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
    Duffy, Austin G.
    Ulahannan, Susanna V.
    Makorova-Rusher, Oxana
    Rahma, Osama
    Wedemeyer, Heiner
    Pratt, Drew
    Davis, Jeremy L.
    Hughes, Marybeth S.
    Heller, Theo
    ElGindi, Mei
    Uppala, Ashish
    Korangy, Firouzeh
    Kleiner, David E.
    Figg, William D.
    Venzon, David
    Steinberg, Seth M.
    Venkatesan, Aradhana M.
    Krishnasamy, Venkatesh
    Abi-Jaoudeh, Nadine
    Levy, Elliot
    Wood, Brad J.
    Greten, Tim F.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (03) : 545 - 551